- Conditions
- HIV Infections
- Interventions
- HIV Therapeutic Biologic Mix - HIV GP160 plus BCG Vaccine Mix for percutaneous use
- Biological
- Lead sponsor
- Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair
- Industry
- Eligibility
- 24 Years to 64 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Rockville, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
- Conditions
- ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- ALECENSA - alectinib hydrochloride capsule
- Drug
- Lead sponsor
- Medicine Invention Design, Inc
- Industry
- Eligibility
- 24 Years to 64 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 2
- States / cities
- Doral, Florida • Rockville, Maryland
- Conditions
- Type 2 Diabetes
- Interventions
- Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes, China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes
- Drug
- Lead sponsor
- Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair
- Industry
- Eligibility
- 24 Years to 64 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Rockville, Maryland
- Conditions
- SCLC
- Interventions
- Topotecan - usual, Topotecan - study
- Drug
- Lead sponsor
- Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair
- Industry
- Eligibility
- 24 Years to 64 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Rockville, Maryland
- Conditions
- Small Cell Lung Cancer
- Interventions
- ETOPOSIDE - Usual, ETOPOSIDE - Study
- Drug
- Lead sponsor
- Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair
- Industry
- Eligibility
- 24 Years to 64 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Rockville, Maryland